A new study from the University of Michigan Rogel Health Cancer Center, published in Science, sheds light on how two distinct classes of mutations in the FOXA1 gene—commonly altered in prostate cancer—drive tumor initiation formation and therapeutic resistance.

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Promising treatment results for blood cancers, colorectal cancer and brain metastases. Novel insights into early pancreatic cancer cell progression. A new therapeutic target for patients with high blood pressure

NRG Oncology (NRG), a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced that Tambre Leighn was appointed Committee Chair of the NRG Patient Advocate Committee (PAC) and Dr. Chris Holsinger was appointed Surgical Vice Chair of the NRG Head and Neck Cancer (HNC) Committee.

A research led by the IBB-UAB has managed to decypher the structure of the human protease SENP5, implicated in neurodegenerative disorders, cardiovascular diseases and the development of cancer. The research, published in Nature Communications, paves the way for therapeutic opportunities with minimal side effects.